Spruce Biosciences (NASDAQ:SPRB - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Spruce Biosciences to post earnings of ($8.8150) per share for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:00 PM ET.
Spruce Biosciences (NASDAQ:SPRB - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($9.58) earnings per share for the quarter, missing analysts' consensus estimates of ($9.16) by ($0.42). On average, analysts expect Spruce Biosciences to post $-31 EPS for the current fiscal year and $-14 EPS for the next fiscal year.
Spruce Biosciences Stock Performance
SPRB stock opened at $57.01 on Tuesday. Spruce Biosciences has a 1 year low of $4.28 and a 1 year high of $240.00. The stock's 50 day moving average price is $60.87 and its 200 day moving average price is $84.65. The firm has a market cap of $78.10 million, a P/E ratio of -1.10 and a beta of 3.62.
Analyst Upgrades and Downgrades
Several analysts have commented on SPRB shares. Weiss Ratings restated a "sell (e+)" rating on shares of Spruce Biosciences in a report on Monday, December 29th. Citizens Jmp lowered their price objective on shares of Spruce Biosciences from $180.00 to $170.00 and set a "market outperform" rating for the company in a research report on Tuesday, March 10th. Craig Hallum began coverage on Spruce Biosciences in a research note on Monday. They set a "buy" rating and a $140.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and issued a $200.00 price target on shares of Spruce Biosciences in a research note on Tuesday, March 10th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Spruce Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $190.60.
Read Our Latest Research Report on Spruce Biosciences
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Cable Car Capital LP acquired a new position in shares of Spruce Biosciences in the 3rd quarter worth approximately $239,000. SkyView Investment Advisors LLC bought a new position in Spruce Biosciences during the fourth quarter worth $261,000. State Street Corp acquired a new position in Spruce Biosciences in the fourth quarter worth $558,000. Superstring Capital Management LP bought a new stake in Spruce Biosciences during the fourth quarter valued at $1,057,000. Finally, Geode Capital Management LLC bought a new position in Spruce Biosciences in the fourth quarter worth about $1,109,000. Institutional investors own 91.71% of the company's stock.
About Spruce Biosciences
(
Get Free Report)
Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.
The company's lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spruce Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spruce Biosciences wasn't on the list.
While Spruce Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
